封面
市场调查报告书
商品编码
1529596

DNA修復药物市场:按药物类型、按应用、按给药途径、按分销管道、按地区

DNA Repair Drugs Market, By Drug Type, By Application, By Route of Administration, By Distribution Channel, By Geography

出版日期: | 出版商: Coherent Market Insights | 英文 206 Pages | 商品交期: 2-3个工作天内

价格
简介目录

预计2024年全球DNA修復药物市场规模为71亿美元,预计2031年将达168亿美元,2024年至2031年复合年增长率为13.1%。

报告范围 报告详情
基准年 2023年 2024年市场规模 71亿美元
实际资料 2019-2023 预测期 2024-2031
2024-2031 年预测期复合年增长率 13.10% 2031 年金额预测 168亿美元
图:2024 年按地区分類的 DNA 修復药物市场占有率(%)
DNA修復药物市场-IMG1

DNA修復药物旨在提高细胞识别和修復受损DNA的能力,并在治疗癌症和其他与基因组不稳定相关的疾病方面具有潜在的应用。人体内的 DNA 会因环境暴露和其他细胞过程而自然磨损,随着时间的推移,可能会导致断裂和其他类型的损伤。正常情况下,细胞具有进化优化的DNA修復途径来修復此类损伤并防止突变累积。然而,某些医疗状况与 DNA 修復能力缺陷有关。透过药物增强 DNA 修復机制可能有助于解决未满足的需求。几家生技公司和大型製药公司正在研究针对修復途径中关键蛋白的 DNA 修復药物,例如 PARP、ATR、ATM 和其他参与DNA损害反应的分子。这一新兴领域有望开发针对癌症和遗传疾病的精准药物。

市场动态:

全球癌症发生率上升以及DNA损伤与各种疾病发展之间的关联性日益增加的临床重要性推动了全球DNA修復药物市场的成长。此外,增加药物研发投资以确定 DNA 修復途径中的分子标靶以及各种候选药物临床试验的进展可能会为市场参与企业提供利润丰厚的机会。然而,与 DNA 生物学相关的复杂性以及与脱靶效应相关的安全风险可能会阻碍充分理解和临床应用。高昂的开发成本也阻碍了市场的开拓。产业参与者正在关註生物标记策略,以选择有反应的患者群体和联合治疗方法,以最大限度地提高疗效,同时最大限度地减少毒性。未来的药物发现工作可能会扩大癌症以外的前景。

本研究的主要特点

  • 该报告对全球DNA修復药物市场进行了详细分析,并提供了以2023年为基准年的预测期(2024-2031年)的市场规模(十亿美元)和年复合成长率(CAGR%)。正在做。
  • 它还揭示了各个细分市场的潜在商机,并解释了该市场中有吸引力的投资提案的矩阵。
  • 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。
  • 它根据公司亮点、产品系列、主要亮点、财务表现和策略等参数,介绍了全球 DNA 修復药物市场的主要企业。
  • 该报告的见解将使负责人和公司经营团队能够就未来的产品发布、产品升级、市场扩张和行销策略做出明智的决策。
  • 全球 DNA 修復药物市场报告迎合了该行业的各种相关人员,如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
  • 相关人员可以透过用于全球 DNA 修復剂市场分析的各种策略矩阵来促进他们的决策。

目录

第一章 研究目的与前提

  • 研究目的
  • 先决条件
  • 简称

第二章 市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要
  • 一致的机会地图 (COM)

第三章 市场动态、法规与趋势分析

  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会
  • 影响分析
  • 市场趋势
  • 监管场景
  • 收购和合作场景
  • 资金筹措和投资
  • PEST分析
  • 波特的分析

第四章全球 DNA 修復药物市场 - 冠状病毒 (COVID-19) 大流行的影响

  • 整体影响
  • 政府倡议
  • COVID-19 对市场的影响

第五章全球DNA修復药物市场,依药物类型,2019-2031(十亿美元)

  • 介绍
  • 尼拉帕尼(Zezura)
  • 奥拉帕尼(LYNPARZA)
  • 鲁卡帕尼(Rubraca)
  • 塔拉佐帕尼(Tarzena)

第六章 全球 DNA 修復药物市场,依应用划分,2019-2031 年(十亿美元)

  • 介绍
  • 卵巢癌
  • 乳癌
  • 摄护腺癌
  • 肺癌
  • 腹膜癌
  • 其他的

第七章 全球 DNA 修復药物市场,依给药途径,2019-2031 年(十亿美元)

  • 介绍
  • 口服
  • 胃肠外的
  • 其他的

第8章全球DNA修復药物市场,按分销管道,2019-2031(十亿美元)

  • 介绍
  • 医院药房
  • 零售药房
  • 网路药房

第9章2019-2031年全球DNA修復药物市场(按地区)(十亿美元)

  • 介绍
  • 拉丁美洲
  • 欧洲
  • 亚太地区
  • 中东

第10章竞争格局

  • 公司简介
    • AstraZeneca PLC
    • Merck &Co., Inc.
    • Merck &Co., Inc.
    • Pfizer Inc.
    • Clovis Oncology
    • Johnson &Johnson Services, Inc.
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • GlaxoSmithKline plc(GSK)
    • Novartis AG
    • Roche Holding AG
    • Agios Pharmaceuticals, Inc.
    • AbbVie Inc.
    • Teva Pharmaceutical Industries Ltd.
    • BioMarin Pharmaceutical Inc.
    • Takeda Pharmaceutical Company Limited
    • NMS Group

第十一章分析师建议

  • 上升和下降
  • 综合机会图

第十二章参考文献与调查方法

  • 参考
  • 调查方法
简介目录
Product Code: CMI2617

Global DNA repair drugs market is estimated to be valued at USD 7.10 Bn in 2024 and is expected to reach USD 16.80 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 13.1% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2024: US$ 7.10 Bn
Historical Data for: 2019 to 2023 Forecast Period: 2024 to 2031
Forecast Period 2024 to 2031 CAGR: 13.10% 2031 Value Projection: US$ 16.80 Bn
Figure. DNA Repair Drugs Market Share (%), By Region 2024
DNA Repair Drugs Market - IMG1

DNA repair drugs aim to improve the ability of cells to identify and repair damaged DNA, which could have applications in treating cancer and other diseases related to genomic instability. DNA in the human body undergoes natural wear and tear from environmental exposures and other cellular processes that can cause breaks and other types of damage over time. Under normal circumstances, cells have evolutionarily optimized DNA repair pathways to fix such lesions and prevent mutations from accumulating. However, certain medical conditions are linked to deficiencies in DNA repair capacity. Enhancing DNA repair mechanisms pharmaceutically could help address unmet clinical needs. Several biotechs and big pharmaceutical firms are researching DNA repair drugs that target key proteins in repair pathways such as PARP, ATR, ATM and other molecules involved in DNA damage response. This budding field holds promise for developing precision medicines for cancer and genetic disorders.

Market Dynamics:

Global DNA repair drugs market growth is driven by rising cancer burden worldwide and growing clinical emphasis on DNA damage links to various disease pathogenesis. Furthermore, increasing pharmaceutical R&D investments to identify molecular targets in DNA repair pathways and ongoing clinical trials for various candidates can offer lucrative opportunities for market players. However, complexities associated with DNA biology and safety risks pertaining to off-target effects can hamper complete understanding and clinical translation. High costs of development can hamper the market growth. Industry players are focused on biomarker strategies to select responder patient populations and combination therapy approaches to maximize efficacy while minimizing toxicity. Future discovery efforts can expand the scope into non-oncology areas.

Key Features of the Study:

  • This report provides in-depth analysis of the global DNA repair drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global DNA repair drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Genentech, Pfizer, AstraZeneca
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global DNA repair drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global DNA repair drugs market

Detailed Segmentation-

  • By Drug Type
    • Niraparib (Zejula)
    • Olaparib (Lynparza)
    • Rucaparib (Rubraca)
    • Talazoparib (Talzenna)
  • By Route of Administration
    • Oral
    • Parenteral
    • Others
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • AstraZeneca PLC
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Clovis Oncology
    • Johnson & Johnson Services, Inc.
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • GlaxoSmithKline plc (GSK)
    • Novartis AG
    • Roche Holding AG
    • Agios Pharmaceuticals, Inc.
    • AbbVie Inc.
    • Teva Pharmaceutical Industries Ltd.
    • BioMarin Pharmaceutical Inc.
    • Takeda Pharmaceutical Company Limited
    • NMS Group

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Type
    • Market Snapshot, By Application
    • Market Snapshot, By Route of Administration
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Regulatory Scenario
  • Acquisitions and Partnerships Scenario
  • Funding and Investments
  • PEST Analysis
  • Porter's Analysis

4. Global DNA Repair Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the Market

5. Global DNA Repair Drugs Market, By Drug Type, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2019 - 2031
    • Segment Trends
  • Niraparib (Zejula)
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Olaparib (Lynparza)
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Rucaparib (Rubraca)
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Talazoparib (Talzenna)
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global DNA Repair Drugs Market, By Application, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2019 - 2031
    • Segment Trends
  • Ovarian Cancer
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Breast Cancer
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Prostate Cancer
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Lung Cancer
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Peritoneal Cancer
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global DNA Repair Drugs Market, By Route of Administration, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2019 - 2031
    • Segment Trends
  • Oral
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Parenteral
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global DNA Repair Drugs Market, By Distribution Channel, 2019 - 2031, (USD Bn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2019 - 2031
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

9. Global DNA Repair Drugs Market, By Region, 2019 - 2031, (USD Bn)

  • Introduction
    • Market Share Analysis, By Region, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, For Region, 2019-2031
    • Regional Trends
      • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
      • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
      • North Africa
      • Central Africa
      • South Africa

10. Competitive Landscape

  • Company Profiles
    • AstraZeneca PLC
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Merck & Co., Inc.
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Clovis Oncology
    • Johnson & Johnson Services, Inc.
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • GlaxoSmithKline plc (GSK)
    • Novartis AG
    • Roche Holding AG
    • Agios Pharmaceuticals, Inc.
    • AbbVie Inc.
    • Teva Pharmaceutical Industries Ltd.
    • BioMarin Pharmaceutical Inc.
    • Takeda Pharmaceutical Company Limited
    • NMS Group

11. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

12. References and Research Methodology

  • References
  • Research Methodology
  • About us and Sales Contact